Sintilimab (PD-1 Antibody) Clinical Trials

1 actively recruiting trial

Also known as: PD-1

Top Sponsors

Cancer Hospital of Guangxi Medical University1

Indications

Sintilimab1
Nasopharyngeal Carcinoma1
Cancer1

Other1 trial

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.